Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Small Lymphocytic Lymphoma: early-phase trial registry
36 of 82 indexed Small Lymphocytic Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #170 of 28,707 conditions by registered trial count.
82 US clinical trials · 36 currently recruiting · #170 of 28,707 conditions by registered trial count
Small Lymphocytic Lymphoma: 82 US clinical trials tracked, 36 recruiting.
Small Lymphocytic Lymphoma is the subject of 82 registered US clinical trials on ClinicalTrials.gov, 36 of them currently open to new participants. 16 are in Phase 3-4 (later-stage) and 62 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition small-lymphocytic-lymphoma
OPEN 36 | RECR 44% | LATE 16 | EARLY 62 | RANK #170 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Acute Lymphoblastic Leukemia (44% recruiting · 132 trials)
Small Lymphocytic Lymphoma lists 36 open slots (44% of 82 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Small Lymphocytic Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Small Lymphocytic Lymphoma is recruiting above its size-band peers.
36 of 82 indexed trials (43.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Small Lymphocytic Lymphoma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 6 of 82 trials (7.3%). 53 distinct sponsors appear on at least one study for this condition label.
-
Typical Small Lymphocytic Lymphoma enrolment sits around 62 participants.
Median target enrolment is 62 among the 82 trials that report a genuine target (sentinel values excluded). 46 of those (56.1%) plan for fewer than 100 participants.
-
Small Lymphocytic Lymphoma research is mostly interventional.
80 interventional and 2 observational studies make up this index (97.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
82 total, page 2 of 2
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Cellectar Biosciences
NCT02952508
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT02629809
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
Mayo Clinic
NCT05677919
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
Memorial Sloan Kettering Cancer Center
NCT04722172
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
M.D. Anderson Cancer Center
NCT02846623
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
NCT01351896
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Jennifer Woyach
NCT02518555
Safe Accelerated Venetoclax Escalation in CLL
Dana-Farber Cancer Institute
NCT04843904
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
NCT02339922
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
National Heart, Lung, and Blood Institute (NHLBI)
NCT02514083
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Jennifer R. Brown, MD, PhD
NCT04624633
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
City of Hope Medical Center
NCT05718869
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
Michael Choi
NCT03422393
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
AbbVie
NCT06291220
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
BeiGene
NCT03734016
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Pharmacyclics
NCT01578707
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
NCT02208037
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
Gilead Sciences
NCT01282424
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
SCRI Development Innovations
NCT01113632
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Massachusetts General Hospital
NCT00644189
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
Ascenta Therapeutics
NCT00275431
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
AbbVie
NCT01682616
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
SCRI Development Innovations
NCT00193518
Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
John Byrd
NCT00201682
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
University of Wisconsin, Madison
NCT00974233
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
MorphoSys
NCT02639910
Imexon for Relapsed Follicular and Aggressive Lymphomas
University of Rochester
NCT01314014
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Tragara Pharmaceuticals
NCT01699152
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Daphne Friedman
NCT00873457
Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
University of California, San Diego
NCT00850057
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Mayo Clinic
NCT03035331
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
David Bond, MD
NCT03892044
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 38 |
| Phase 3 | 16 |
Top Sponsors
Named interventions
Most-linked intervention names on Small Lymphocytic Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Small Lymphocytic Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Small Lymphocytic Lymphoma page
82 registered trials, 36 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 36 Small Lymphocytic Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Small Lymphocytic Lymphoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Small Lymphocytic Lymphoma condition card totals 82 registered trials; most-linked intervention Venetoclax; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.